Loading
companiesCompany
Mabwell (Shanghai) Bioscience
Mabwell (Shanghai) Bioscience is a China-based biotechnology company running 11 late-stage cancer trials of Toripalimab (JS001 ) and JS207 in bladder & urothelial cancer, cervical cancer and colorectal cancer.
Also called: Mabwell (Shanghai) Bioscience Co., Ltd.
Overview
Mabwell (Shanghai) Bioscience, based in Shanghai, China, is a biotechnology company listed as 688062.SH, 02493.HK. Mabwell is an innovation-driven biopharmaceutical company covering the full chain of antibody drug research, manufacturing and commercialisation, with several marketed monoclonal antibody and biosimilar products. On ClinicalTrials.gov it is the lead sponsor of 11 recruiting or active phase 2 and phase 3 interventional cancer trials (3 in phase 3), testing Toripalimab (JS001 ) and JS207 in bladder & urothelial cancer, cervical cancer, colorectal cancer and triple-negative breast cancer. The largest, NCT06592326 (9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer), plans to enrol 460 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Similar pages
- CancerMuscle-invasive and advanced bladder cancer
Shares A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer, 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma, 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer, 9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer.
- TreatmentToripalimab
Shares 9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer, 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma, 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer, 9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer.
cancers
trials
9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial CancerA Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast CancerA Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid TumorsA Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior ChemoimmunotherapyA Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast CancerA Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial CancerA Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical CancerFirst-in-human Study of 7MW4911 in GI CancerFirst-in-human Study of 7MW4911 in Patients With Advanced Solid TumorsPhase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors